Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.25%

Regeneron's strong EPS performance indicates effective cost management and possibly strong sales of its products. The stock's 4.25% increase reflects investor optimism following the earnings report. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$12.56	N/A	+53.62%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Confident

Management expressed confidence in the company's performance and future prospects. They highlighted their commitment to innovation and product development.

We are pleased with our strong EPS performance this quarter.

Our focus remains on innovation and expanding our product pipeline.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.25%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.25%

Key numbers

Management commentary